靶向PD-1／PD-L1通路的肿瘤分子显像研究进展

The state of the art of tumor molecular imaging targeting PD-1/PD-L1 pathway

程序性细胞死亡蛋白-1/程序性细胞死亡配体-1（PD-1/PD-L1）信号通路是肿瘤免疫治疗的新靶点。抗PD-1抗体和抗PD-L1抗体可阻断PD-1/PD-L1信号通路，在多种实体瘤治疗中具有良好的疗效和安全性。临床试验显示，肿瘤PD-L1的表达与患者的临床分期及不良预后相关。肿瘤PD-L1的检测有助于筛选抗PD-1/PD-L1免疫治疗的优势人群及评估其预后。而以PET、SPECT及光学成像为代表的分子影像技术为检测多种标志物的表达提供了有力手段，可无创、动态、整体三维展示标志物的表达和分布。该文综述了靶向PD-1/PD-L1通路的肿瘤分子显像研究进展。

Programmed cell death protein-1/programmed cell death ligand-1 （PD-1/PD-L1） pathway has emerged as a critical target for cancer immunotherapy, and monoclonal antibodies that block either side of this inhibitory interaction have demonstrated impressive activity across a broad set of cancer subtypes. Clinical studies have shown that tumor PD-L1 expression is associated with clinical stages and poor prognosis. Tumor PD-L1 expression detection may help to screen the patients who are most likely to be benefit from anti-PD-1/PD-L1 therapy and evaluate the prognosis. Molecular imaging technology such as PET, SPECT and optical imaging may be the modalities that allowing for noninvasively dynamic detection and overall evaluation of multiple biomarkers. This review focuses on the state of the art of tumor molecular imaging targeting PD-1/PD-L1 pathway.